Overview
Compare with Serina Therapeutics, Inc., SOLIGENIX, INC. or BullFrog AI Holdings, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-100.0%Revenue growth, 20252
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-08-31 | 2024-08-31 |
|---|---|---|
| Revenues | $0 | $130.1K |
| Research and development expense | $0 | $194.8K |
| General and administrative expenses | $271.7K | $518.4K |
| Total operating expenses | $271.7K | $713.2K |
| Loss from operations | -$271.7K | -$583.1K |
| Capital loss | $0 | $88.9K |
| Financial loss, net | $42.3K | $23.1K |
| Net (loss) income | -$314.0K | -$695.2K |
| Total comprehensive (loss) income | -$314.0K | -$695.2K |
| Net (loss) per share - basic | $0.00 | -$0.02 |
| Net (loss) per share - diluted | $0.00 | -$0.02 |
| Weighted average number of shares outstanding - Basic | 90.6M shares | 30.2M shares |
| Weighted average number of shares outstanding - Diluted | 90.6M shares | 30.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 |
|---|---|---|---|
| Cash and cash equivalents | $15.1K | $26.4K | |
| Prepaid expenses and other receivables | $3.3K | $5.0K | |
| Total current assets | $18.4K | $31.4K | |
| Equipment, net | $0 | $0 | |
| Total assets | $18.4K | $31.4K | |
| Accounts payable and accrued liabilities | $49.3K | $40.8K | |
| Convertible loan | $1.2M | $1.3M | |
| Due to a related party | $1.3M | $1.2M | |
| Total current liabilities | $2.5M | $2.5M | |
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.0001 par value, 1,800,000,000 and 900,000,000 shares authorized on August 31, 2025 and August 31, 2024 respectively. 553,962,206 and 31,111,352 shares issued and outstanding on August 31, 2025 and August 31, 2024 respectively | $55.4K | $3.1K | |
| Additional paid-in capital | $22.7M | $22.5M | |
| Accumulated deficit | -$25.3M | -$25.0M | |
| Total stockholders' equity (deficit) | -$2.5M | -$2.5M | -$2.0M |
| Total liabilities and stockholders' equity | $18.4K | $31.4K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.8B shares | 900.0M shares | |
| Common stock, shares issued | 554.0M shares | 31.1M shares | |
| Common stock, shares outstanding | 554.0M shares | 31.1M shares |
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 |
|---|---|---|---|
| Cash and cash equivalents | $15.1K | $26.4K | |
| Prepaid expenses and other receivables | $3.3K | $5.0K | |
| Total current assets | $18.4K | $31.4K | |
| Equipment, net | $0 | $0 | |
| Total assets | $18.4K | $31.4K | |
| Accounts payable and accrued liabilities | $49.3K | $40.8K | |
| Convertible loan | $1.2M | $1.3M | |
| Due to a related party | $1.3M | $1.2M | |
| Total current liabilities | $2.5M | $2.5M | |
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.0001 par value, 1,800,000,000 and 900,000,000 shares authorized on August 31, 2025 and August 31, 2024 respectively. 553,962,206 and 31,111,352 shares issued and outstanding on August 31, 2025 and August 31, 2024 respectively | $55.4K | $3.1K | |
| Additional paid-in capital | $22.7M | $22.5M | |
| Accumulated deficit | -$25.3M | -$25.0M | |
| Total stockholders' equity (deficit) | -$2.5M | -$2.5M | -$2.0M |
| Total liabilities and stockholders' equity | $18.4K | $31.4K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.8B shares | 900.0M shares | |
| Common stock, shares issued | 554.0M shares | 31.1M shares | |
| Common stock, shares outstanding | 554.0M shares | 31.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-08-31 | 2024-08-31 |
|---|---|---|
| Net (Loss) | -$314.0K | -$695.2K |
| Depreciation | $0 | $72.3K |
| Share based payment | $0 | $139.7K |
| Interest on Convertible loan | $39.8K | $16.8K |
| Capital loss (Gain) | $0 | $88.9K |
| Accounts Receivable and prepaid expenses | $1.6K | $89.6K |
| Accounts payable and accrued liabilities | $101.2K | $43.5K |
| Net cash used in operating activities | -$171.3K | -$244.3K |
| Sale of equipment | $0 | $114.7K |
| Acquisition of equipment | $0 | -$1.2K |
| Net cash used in investing activities | $0 | $113.5K |
| Proceeds from issuance of a Convertible loan | $160.0K | $27.5K |
| Net cash provided by financing activities | $160.0K | $27.5K |
| Net increase (decrease) in cash | -$11.3K | -$103.3K |
| Exercise of a Convertible loan to shares of common stock. | $297.7K | $92.8K |
No quarter-by-quarter statement was filed.
Corporate structure
CNBX Pharmaceuticals Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of CNBX Pharmaceuticals Inc.
- 3i, LP Filed SCHEDULE 13G/A on CNBX Pharmaceuticals Inc., latest Aug 14, 2026 (10 filings since Mar 6, 2023)
- CNBX Pharmaceuticals Inc. Bethesda, Maryland
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What CNBX Pharmaceuticals Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
Investments
Leadership
Who has led CNBX Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2010201520202025
- Chief executive officerThomas E. Mills Apr 12, 2006 to Sep 26, 200713
- PresidentThomas E. Mills Apr 12, 2006 to Sep 26, 200713
- PresidentLou Hilford Apr 13, 2006 to Apr 13, 200614
- Chief financial officerThomas E. Mills Apr 12, 2006 to Sep 26, 200713
Board members and other officers (2)
- Board memberThomas E. Mills Apr 12, 2006 to Sep 26, 200713
- Board memberLou Hilford Apr 13, 2006 to Apr 13, 200614
Former names
Timeline
- Oct 1, 20268-K Change of auditor15
- Mar 17, 20268-K Entered a material agreement16
- Jan 30, 20258-K Entered a material agreement17
- Mar 22, 20248-K Change of auditor18
- Feb 8, 20238-K Executive or director change19
- Dec 29, 20228-K Executive or director change20
- Jul 25, 20228-K Executive or director change21
- May 13, 20228-K Bylaws or fiscal year changed22
- Mar 28, 20228-K Bylaws or fiscal year changed; Other events23
- Mar 16, 20228-K Entered a material agreement; New debt or obligation24
- Feb 17, 20228-K Entered a material agreement25
- Nov 19, 20218-K Executive or director change26
- Apr 12, 2006New chief executive Thomas E. Mills becomes CEO13
Filings
54 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 12 major events, 10 large holders, 12 other. The latest 20:
- Oct 1, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Jun 24, 202610-Q FORM 10-Q FOR MAY 2026 EDGAR
- May 8, 2026SCHEDULE 13G/A EDGAR
- Apr 14, 202610-Q EDGAR
- Mar 17, 20268-K EDGAR
- Feb 5, 2026SCHEDULE 13G/A EDGAR
- Jan 14, 202610-Q QUARTERLY REPORT EDGAR
- Dec 1, 202510-K FORM 10-K FOR AUG 2025 EDGAR
- Nov 10, 2025SCHEDULE 13G/A EDGAR
- Aug 13, 2025SCHEDULE 13G/A EDGAR
- Jul 14, 202510-Q EDGAR
- May 13, 2025SCHEDULE 13G/A EDGAR
- Apr 14, 202510-Q EDGAR
- Feb 13, 2025SCHEDULE 13G/A EDGAR
- Jan 30, 20258-K EDGAR
- Jan 13, 202510-Q FORM 10-Q FOR NOV 2024 EDGAR
- Nov 29, 202410-K FORM 10-K FOR AUGUST 2024 EDGAR
- Nov 14, 2024SC 13G/A EDGAR
- Jul 15, 202410-Q EDGAR
The 54 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
SEC filer profile
How CNBX Pharmaceuticals Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCNBX Pharmaceuticals Inc.1
- CIK0001343009
- Employer ID (EIN)20-337366928
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company28
- Incorporated inNevada28
- Fiscal year endsAugust 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address#3 Bethesda Metro Center, Suite 700, Bethesda, MD 208141
- Phone877-424-24291
- Shares outstanding1,605,768,095 as of Jun 17, 202612
- Public float$251.8K as of Aug 31, 202528
- AuditorElkana Amitai. C.P.A., Mitzpe Netofa, Israel PCAOB ID 6816; no auditor attestation of internal control over financial reporting28
- On EDGAR sinceJan 9, 20061
- Filings301 in all: 8-K (80), 10-Q (54), CORRESP (22), UPLOAD (18), 10-K (17), 10-Q/A (9), 4 (9), NT 10-Q (8)1
All 37 form types
10QSB (7), SCHEDULE 13G/A (7), NT 10-K (5), SC 13D (5), SC 13D/A (5), 10-K/A (4), 3 (4), 424B2 (4), EFFECT (4), S-1 (4), S-1/A (4), 10KSB (3), 10KSB/A (3), 4/A (3), 424B5 (2), 8-K/A (2), DEF 14C (2), PRE 14C (2), SB-2/A (2), SC 13G (2), SC 13G/A (2), 10QSB/A (1), 144 (1), 424B3 (1), 8-A12G (1), RW (1), S-3 (1), S-3/A (1), SB-2 (1)
- Latest filingsAnnual report (10-K) Dec 1, 2025
Quarterly report (10-Q) Jun 24, 2026
Latest 8-K (8-K) Oct 1, 2026
Risk factors and legal proceedings
The risks CNBX Pharmaceuticals Inc. names in Item 1A of its 10-K filed Dec 1, 2025: 49 risks under these headings, as written.28
- You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing the Company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects.
- Risks Related to Our Company and Business
- Our independent auditors have expressed substantial doubt about our ability to continue operating as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
- We have not generated any significant revenue since our inception and we may never achieve profitability.
- Since we have a limited operating history in our business, it is difficult for potential investors to evaluate our business.
- We will need to raise additional capital to meet our business requirements in the future, which may be costly or difficult to obtain and could dilute our stockholders’ ownership interests.
- We are highly dependent on the success of cannabinoid technology, and we may not be able to develop the technology, successfully obtain regulatory or marketing approval for, or successfully commercialize, our products or product candidates.
- Our success depends upon our ability to retain our senior management and our ability to attract, retain and motivate other qualified personnel.
- The relative lack of public company experience by our management team may put us at a competitive disadvantage.
- If we are unable to enter into acceptable sales, marketing and distribution arrangements with third parties or establish sales, marketing and distribution capabilities, we may not be successful in commercializing any product candidate that we develop if and when a product candidate is approved.
- We face intense competition, often from companies with greater resources and experience than we have, which may result in others developing or commercializing competing products before us or more successfully.
- If we are unable to compete successfully, there may be a material and adverse effect on our business, financial condition and results of operations.
The other 38 risks
- We are exposed to potential product liability risks that are inherent in the testing, manufacturing and marketing of cancer diagnostics, pharmaceuticals and dietary supplements.
- If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected.
- Costly litigation may be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights of others.
- Failure in our information technology or storage systems could significantly disrupt our operations and our research and development efforts, which could adversely impact our revenues, as well as our research, development and commercialization efforts.
- We will need to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.
- We are subject to financial reporting and other requirements that place significant demands on our resources.
- Risks Related to Cannabis
- Our failure to comply with controlled substance legislation could restrict or harm our ability to develop and commercialize our products.
- Cannabis remains illegal under U.S. federal law, and any change in the enforcement priorities of the federal government could render our current and planned future operations unprofitable or even prohibit such operations.
- Our ability to earn revenue through licensing our product in the United States is dependent on additional states legalizing medical marijuana.
- Changes in consumer preferences and acceptance of medical cannabis, or any negative trends, will adversely affect our business.
- Risks Related to Product Development
- If we fail to successfully develop and commercialize diagnostics, pharmaceutical or therapies, we may be unable to execute our plan of operations.
- Our clinical diagnostics may never be validated.
- The Federal Food and Drug Administration may impose additional regulatory obligations and costs upon the development of our diagnostics.
- Changes in laws and regulations concerning clinical diagnostic tests may adversely affect our business, financial condition and results of operations.
- We may fail to demonstrate the safety and efficacy of our therapeutic product candidates in accordance with regulatory standards and may incur delays and substantial costs in our clinical trials.
- We cannot predict if or when we will receive regulatory approval to commercialize a therapeutic product candidate.
- Even if we obtain regulatory approval for a therapeutic product candidate, we will remain subject to extensive regulatory scrutiny.
- We may fail to obtain orphan drug status for our therapeutic product candidates.
- Any of our therapeutic product candidates may cause adverse effects or have properties that could delay or prevent their regulatory approval or limit the scope of any specific indications or market acceptance.
- Our dietary supplements are subject to government regulation, both in the United States and internationally, which could increase our costs significantly and limit or prevent the sale of our dietary supplements.
- Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
- Risks Related to Our Dependence on Third Parties
- We rely and expect to continue to rely heavily on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies and trials.
- Collaboration agreements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our diagnostics and therapeutic product candidates.
- Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.
- Our business model is substantially dependent on third party licensees to market and sell our products, which will subject us to a number of risks.
- Risks Related To Operating In Israel
- Failure to secure the necessary Israeli licenses to use cannabis for medical research could limit our ability to execute our research and development activities, delay the launch of our products and adversely affect the results of our business operations.
- We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.
- We expect that our results of operations will be subject to fluctuations in currency exchange rates because a substantial portion of our anticipated revenue will be generated in U.S. dollars and Euros while a significant portion of our expenses will be incurred in New Israeli Shekels.
- We may not be able to enforce covenants not-to-compete under current Israeli law.
- It may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.
- If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business relationships and profitability.
- Risks Related to Our Stock
- There can be no assurance of an active, liquid and orderly trading market for our common stock or that investors will be able to sell their shares of common stock.
- The price of our common stock is volatile, and the value of your investment could decline.
- We may never pay any dividends to our shareholders.
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
- We may issue shares of preferred stock with greater rights than our common stock, which may entrench management and result in dilution of our stockholders' investment.
- Nevada law and certain provisions of our Articles of Incorporation and bylaws may discourage mergers and other transactions.
- Our common stock may be subject to penny stock rules, which may make it more difficult for our investors to sell their common stock.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARLou Hilford, President
- 15SEC EDGARChange of auditor
- 16SEC EDGAREntered a material agreement
- 17SEC EDGAREntered a material agreement
- 18SEC EDGARChange of auditor
- 19SEC EDGARExecutive or director change
- 20SEC EDGARExecutive or director change
- 21SEC EDGARExecutive or director change
- 22SEC EDGARBylaws or fiscal year changed
- 23
- 24
- 25SEC EDGAREntered a material agreement
- 26SEC EDGARExecutive or director change
- 27
- 28